Read by QxMD icon Read

Meningococcal vaccinations

Heidi M Soeters, Jill Dinitz-Sklar, Prathit A Kulkarni, Jessica R MacNeil, Lucy A McNamara, Elizabeth Zaremski, How-Yi Chang, Eduardo Lujan, Dan Granoff, Melodee Lasky, Barbara Montana
In response to a university-based serogroup B meningococcal disease outbreak, the serogroup B meningococcal vaccine Trumenba was recommended for students, a rare instance in which a specific vaccine brand was recommended. This outbreak highlights the challenges of using molecular and immunologic data to inform real-time response.
May 2017: Emerging Infectious Diseases
Maria Serena Gallone, Carmen Martino, Michele Quarto, Silvio Tafuri
In 2014, an Italian hospital implemented a protocol for pneumococcal, meningococcal, and Haemophilus influenzae type b vaccines offer to splenectomized patients during their hospitalization. After 1 year, coverage for recommended vaccinations increased from 5.7%-66.7% and the average time between splenectomy and vaccines administration decreased from 84.7-7.5 days.
April 11, 2017: American Journal of Infection Control
Helen Campbell, Michael Edelstein, Nick Andrews, Ray Borrow, Mary Ramsay, Shamez Ladhani
During the first 12 months of an emergency meningococcal ACWY vaccination program for teenagers in England, coverage among persons who left school in 2015, the first cohort to be vaccinated, was 36.6%. There were 69% fewer group W meningococcal cases than predicted by trend analysis and no cases in vaccinated teenagers.
July 15, 2017: Emerging Infectious Diseases
Nicola J Beresford, Angela Martino, Ian M Feavers, Michael J Corbel, Xilian Bai, Ray Borrow, Barbara Bolgiano
A physicochemical and immunological study of the stability of three different meningococcal (Men) ACWY conjugate vaccines was performed to evaluate any patterns of serogroup oligo- or polysaccharide-specific or carrier protein-specific stability that would affect immunogenicity. Critical quality and stability-indicating characteristics were measured, with the study supporting the suitability of both HPLC-SEC and HPAEC-PAD methods to detect changes following inappropriate vaccine storage. All three final products, ACWY-CRM197, -DT and -TT conjugate vaccines had expected quality indicator values and similar immunogenicity in a mouse model (anti-PS IgG and rSBA) when stored at +2-8°C...
April 10, 2017: Vaccine
Joy Seanehia, Carole Treibich, Christine Holmberg, Jacqueline Müller-Nordhorn, Valerie Casin, Jocelyn Raude, Judith E Mueller
BACKGROUND: Several concepts are available to explain vaccine decision making by individual and inter-individual factors, including risk perception, social conformism and altruism. However, only a few studies have quantified the weight of these determinants in vaccine acceptance. Using a conjoint analysis tool, we aimed at eliciting preferences in a student population regarding vaccination against a rare, severe and rapidly evolving hypothetical disease, similar to meningococcal serogroup C meningitis or measles...
April 10, 2017: Vaccine
Susu M Zughaier
The protective effect of meningococcal vaccines targeting disease causing serogroups exemplified by the introduction of MenAfriVac™ in Africa, is well established and documented in large population-based studies. Due to the emergence of other meningococcal disease causing serogroups, novel vaccine formulations are needed. There is a high potential for novel nanotechnology-based meningococcal vaccine formulations that can provide wider vaccine coverage. The proposed meningococcal vaccine formulation contains spherical shaped micro and nanoparticles that are biological mimics of Niesseria meningitidis, therefore present to immune system as invader and elicit robust immune responses...
April 10, 2017: Human Vaccines & Immunotherapeutics
Caroline Vipond, Carolyn J Swann, Thomas W Dougall, Peter Rigsby, Fang Gao, Nicola J Beresford, Barbara Bolgiano
Polysaccharide (PS) based meningococcal vaccines are primarily evaluated by physicochemical methods to ensure batches are consistently manufactured. As PS content is determined by different methods across numerous laboratories, there is a need for International Standards (IS) to calibrate the assays. Following the successful introduction of the WHO Meningococcal group C (MenC) IS in 2011, NIBSC initiated projects to prepare similar standards for groups A, W, Y and X (MenA/W/Y/X) to standardise all meningococcal- PS based vaccines...
April 4, 2017: Biologicals: Journal of the International Association of Biological Standardization
Carlos Espinosa-Viñals, Dagmar García-Rivera, Laura Rodríguez Noda, Aylín Amador Gómez, Milagros Nicot, Orialys Valle, Juan F Núñez, Yanet Martin, Darielys Santana, Yury Valdés, Vicente Vérez Bencomo
Finlay Vaccine Institute is developing a new heptavalent conjugate vaccine against Streptococcus pneumoniae. As infants are the target population, PCV7-TT will be necessarily co-administered with other vaccines, and then, the interactions represent a concern. The aim of this work is to evaluate the possible immunological interferences in rabbits as animal experimental model. Rabbits were immunized with Heberpenta®-L, VA-MENGOC-BC®, and PCV7-TT. Blood samples were taken fourteen days after final immunization for obtaining sera...
April 5, 2017: Immunological Investigations
Mohamed Tashani, Leon Heron, Melanie Wong, Harunor Rashid, Robert Booy
Background: : Due to their antigenic similarities, there is a potential for immunological interaction between tetanus/diphtheria-containing vaccines and carrier proteins presented on conjugate vaccines. The interaction could, unpredictably, result in either enhancement or suppression of the immune response to conjugate vaccines if they are injected soon after or concurrently with diphtheria or tetanus toxoid. We examined this interaction among adult Australian travellers before attending the Hajj pilgrimage of 2015...
July 1, 2017: Journal of Travel Medicine
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani, Rino Rappuoli
The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials...
April 10, 2017: Expert Review of Vaccines
Manish Sadarangani, Sheula Barlow, Mark Anthony, Andrew J Pollard
No abstract text is available yet for this article.
March 20, 2017: Journal of the Pediatric Infectious Diseases Society
Myron Christodoulides, John Heckels
A range of vaccines is available for preventing life-threatening diseases caused by infection with Neisseria meningitidis (meningococcus, Men). Capsule polysaccharide (CPS)-conjugate vaccines are successful prophylactics for serogroup MenA, MenC, MenW and MenY infections and outer membrane vesicle (OMV) vaccines have been used successfully for controlling clonal serogroup MenB infections. MenB vaccines based on recombinant proteins identified by reverse vaccinology (Bexsero®) and proteomics (Trumenba®) approaches have recently been licensed and Bexsero® has been introduced into the UK infant immunization program...
March 22, 2017: Pathogens and Disease
Carolyn M Buckwalter, Elissa G Currie, Raymond S W Tsang, Scott D Gray-Owen
Background: The 4CMenB vaccine is an outer membrane vesicle and recombinant protein-based vaccine recently licensed to protect against serogroup B meningococcal disease. It remains unknown whether this vaccine will prevent carriage or transmission, key aspects in long-term vaccine success and disease eradication. Methods: Employing a 'humanized' transgenic mouse model of nasal colonization, a systematic approach was taken to estimate the potential for carriage prevention against antigenically-diverse Neisseria meningitidis strains, and to compare this protection to an invasive meningococcal disease challenge model...
March 27, 2017: Journal of Infectious Diseases
Sydel R Parikh, Lynne Newbold, Stephanie Slater, Maria Stella, Monica Moschioni, Jay Lucidarme, Rosita De Paola, Maria Giuliani, Laura Serino, Stephen J Gray, Stephen A Clark, Jamie Findlow, Mariagrazia Pizza, Mary E Ramsay, Shamez N Ladhani, Ray Borrow
BACKGROUND: The UK introduced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisation programme in September, 2015. The Meningococcal Antigen Typing System (MATS) was used to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 in England and Wales (MATS coverage). We aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15, before 4CMenB introduction; compare strain coverage between 2007-08 and 2014-15; and investigate associations between MATS coverage, age, region, and disease outcomes...
March 30, 2017: Lancet Infectious Diseases
Jonathan Duffy, Peter Johnsen, Mary Ferris, Mary Miller, Kevin Leighton, Mark McGilvray, Lucy McNamara, Lucy Breakwell, Yon Yu, Tina Bhavsar, Elizabeth Briere, Manisha Patel
OBJECTIVE: To assess the safety of MenB-4C vaccine. PARTICIPANTS: Undergraduates, dormitory residents, and persons with high-risk medical conditions received the MenB-4C vaccine two-dose series during mass vaccination clinics from 12/2013 through 11/2014. METHODS: Adverse events (AEs) were identified by 15 minutes of observation post-vaccination, spontaneous reports, surveys, and hospital surveillance. Causality was assessed for serious adverse events (SAEs)...
March 31, 2017: Journal of American College Health: J of ACH
D P J Turner, N J Oldfield, C D Bayliss
No abstract text is available yet for this article.
April 2017: Public Health
Ian M Feavers, Martin C J Maiden
The widespread use of meningococcal polysaccharide conjugate vaccines has highlighted the challenge of providing protection against serogroup B disease. Over a period of four decades vaccine development has focused on sub-capsular, protein antigens, first with outer membrane vesicle (OMV) vaccines against epidemic outbreaks, and more recently on new multicomponent vaccines designed to offer better cross-protection against the antigenically diverse strains responsible for endemic disease. Because of the low incidence of meningococcal disease, the protective efficacy of these vaccines has not been determined in clinical studies and their licensure has been based on serological data; however, the serological assays used to predict protective coverage have limitations...
March 29, 2017: Clinical and Vaccine Immunology: CVI
Mohammad Irfan Azeem, Mohamed Tashani, Al-Mamoon Badahdah, Leon Heron, Kristen Pedersen, Neisha Jeoffreys, Jen Kok, Elizabeth Haworth, Dominic E Dwyer, Grant Hill-Cawthorne, Harunor Rashid, Robert Booy
AIM: To estimate the pharyngeal carriage rate of Neisseria meningitidis (N. meningitidis), Streptococcus pneumoniae (S. pneumoniae) and Staphylococcus aureus (S. aureus) among Australian Hajj pilgrims. METHODS: In 2014, surveillance was conducted in two phases among Australian Hajj pilgrims: The first phase during Hajj in Mina, and the second phase soon after returning home to Australia. Nasopharyngeal or oropharyngeal swabs were taken from participants then tested, firstly by nucleic acid testing, and also by standard culture...
March 16, 2017: World Journal of Clinical Cases
Fenglin Shi, Aiyu Zhang, Bingqing Zhu, Yuan Gao, Li Xu, Yixing Li, Zundong Yin, Junhong Li, Na Xie, Zhujun Shao
OBJECTIVE: To study the prevalence of the fHbp genes in Neisseria meningitidis (N. meningitidis) isolates for further evaluation and development of serogroup B meningococcal vaccines in China. METHODS: A panel of 1012 N. meningitidis strains was selected from the national culture collection from 1956 to 2016, according to the years of isolation, locations, and strain sources. These were tested by FHbp variant typing. Multi-locus sequence typing (MLST) was performed on 822 of these samples, including 242 strains from clinical strains and 580 carrier-derived strains...
March 25, 2017: Vaccine
D M MacDougall, J M Langley, L Li, L Ye, D MacKinnon-Cameron, K A Top, S A McNeil, B A Halperin, A Swain, J A Bettinger, E Dubé, G De Serres, S A Halperin
OBJECTIVES: During an outbreak of invasive meningococcal B disease on a university campus, we explored the knowledge, attitudes, beliefs, and behaviors of members of the university community in relation to the disease, the vaccine, and the vaccination program. DESIGN: All students, faculty and staff were invited by email to participate in a 71-item online survey, which was administered after completion of the mass clinics for the first and second doses of a meningococcal B vaccination program...
March 24, 2017: Vaccine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"